PET3D Conference cancelled due to COVID-19 crisis
May 28, 2020, Loughborough University, UK
Keynote speaker Marc Robillard, Tagworks Pharmaceutical
Radiopharmaceuticals in Drug Design and Development:
- “Theranostics: combining Imaging and Therapy”
Ciara Finucane, Vice President, Discovery & Preclinical Services, Invicro
- “De-risking PET Radioligand Development with the 3 P’s: Pharmacology, Pharmacology, Pharmacology”
Lisa Wells, Head of Discovery CNS Applications, Invicro
- “PET in Early Phase Oncology Trials”
Jan Passchier, Global Head of Laboratories and Clinics, Invicro
This conference is the Final Dissemination Event of the PET3D project, a 4 year EU Marie Sklodowska-Curie Actions training programme for Early Stage Researchers. The aim of the programme is to train the next generation of translational Positron Emission Tomography (PET) imaging scientists who will play a key role in shaping the future of drug design and development.
Find out about the cutting edge research projects in the three main therapeutic areas of oncology, cardiovascular and central nervous system
Find out how we are using PET in Drug Design and Development.
Meet the collaborating PIs from: Loughborough ,UK (Coordinating University); CIC biomaGUNE, Spain; AstraZeneca plc, Sweden; Invicro, UK; Stichting VUMC, The Netherlands; University of Bergen, Norway; Vrije Universiteit Brussel, Belgium; Westfaelische Wilhelms-Universitaet, Muenster, Germany
Keynote External Speaker
Dr Marc Robillard
Radiopharmaceuticals in Drug Design and Developments
Speakers from Invicro, UK will give key talks as part of a PET3D Summer School training event within the PET3D conference.
Ciara Finucane, Vice President, Discovery & Preclinical Services
Lisa Wells, Head of Discovery CNS Applications
Jan Passchier, Global Head of Laboratories and Clinics
How PET can be used in Drug Design and Development
PET is a non-invasive and highly sensitive imaging technology developed to visualise and quantify biochemical and physiological processes in vivo.
Although the PET3D consortium will not develop drugs, it will make a significant contribution to drug development by validating PET imaging in different therapeutic areas.
Within the consortium we have leading experts – from 8 different institutions situated all over Europe – in medicinal and organic chemistry, peptide and protein chemistry, radiochemistry, pharmacology, cell and preclinical biology, molecular biology, molecular imaging, image analysis and radiology.
All beneficiaries of the project have a PET centre onsite with the exception of AstraZeneca, which is the ‘big pharma’ partner whose role is to provide a proof-of principle validation and essential input on the research activity developed within PET3D.
ESR Featured Talks
Top students from across the world have been recruited to come together to train in world-class, innovative reasearch using PET imaging.
They will share their thoughts and experiences of the Marie Sklodowska-Curie Actions Innovative Training Network (MSCA-ITN).
How they heard about the PET3D project
Why they chose a MSCA-ITN project.
What is next…
1. Loughborough University
2. Stichting VUMC
3. Vrije Universiteit
4. University of Bergen
5. CIC bioMAGUNE
6. Westfaelische Wilhelms Universitaet Muenster
8. AstraZeneca plc